Mineralys Therapeutics, Inc. (MLYS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Mineralys Therapeutics reported revenue of $0. Net income was -$154.7M, or -$2.29 per diluted share. Operating activities generated -$142.4M of cash, leaving -$142.4M of free cash flow. At fiscal year end, Mineralys Therapeutics held $661.8M in total assets against $15.1M in total liabilities, including $172.9M of cash and equivalents.
Open the full interactive Mineralys Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Mineralys Therapeutics Key Stats
| Share Price | $21.00 |
|---|---|
| Market Cap | $1.78B |
| 52-Week Range | $21.00 – $47.33 |
| Shares Outstanding | 84.7 million (basic, 2026 Q2) |
Mineralys Therapeutics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating Income | -$84.7M | -$192.4M | -$170.6M |
| Pre-Tax Income | -$71.9M | -$177.8M | -$154.7M |
| Income Tax | — | — | $0 |
| Net Income | -$71.9M | -$177.8M | -$154.7M |
| Diluted EPS | -$1.99 | -$3.66 | -$2.29 |
Mineralys Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$36.9M | -$32.2M | -$39.3M | -$241.1M |
| Diluted EPS | -$0.52 | -$0.48 | -$0.47 | -$2.85 |
Mineralys Therapeutics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $49.3M | $114.1M | $172.9M |
| Current Assets | $249.1M | $205.4M | $661.4M |
| Total Assets | $251.6M | $205.9M | $661.8M |
| Current Liabilities | $10.5M | $14.6M | $15.1M |
| Total Liabilities | $10.5M | $14.6M | $15.1M |
| Shareholders' Equity | $241.2M | $191.3M | $646.7M |
Mineralys Therapeutics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$81.2M | -$166.3M | -$142.4M |
| Cash From Investing | -$160.5M | $115.0M | -$389.8M |
| Cash From Financing | $203.2M | $116.1M | $591.0M |
| Free Cash Flow | -$81.2M | -$166.3M | -$142.4M |
Figures from Mineralys Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Mineralys Therapeutics financials page for every line item.
Mineralys Therapeutics Company Profile
| Ticker | MLYS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Radnor, Pennsylvania |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001933414 |
Frequently Asked Questions
What was Mineralys Therapeutics' revenue in fiscal 2025?
Mineralys Therapeutics (MLYS) reported revenue of $0 for fiscal 2025.
What is Mineralys Therapeutics' annual revenue history?
Mineralys Therapeutics' annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $0.
What was Mineralys Therapeutics' net income in fiscal 2025?
Mineralys Therapeutics reported net income of -$154.7M for fiscal 2025.
What was Mineralys Therapeutics' earnings per share (EPS) in fiscal 2025?
Mineralys Therapeutics' diluted EPS was -$2.29 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Mineralys Therapeutics generate in fiscal 2025?
Mineralys Therapeutics generated -$142.4M of free cash flow in fiscal 2025.
What was Mineralys Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Mineralys Therapeutics reported revenue of $0.
How many shares of Mineralys Therapeutics are outstanding?
Mineralys Therapeutics reported a weighted average of 84.7 million basic shares outstanding in 2026 Q2.
What is Mineralys Therapeutics' market cap?
Based on its latest closing price, Mineralys Therapeutics (MLYS) has a market capitalization of about $1.78B.
When does Mineralys Therapeutics' fiscal year end?
Mineralys Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Mineralys Therapeutics headquartered?
Mineralys Therapeutics lists its business address in Radnor, Pennsylvania in its SEC filings.